Impact of tirzepatide on FIB-4 in patients with type 2 diabetes

Impact of tirzepatide on FIB-4 in patients with type 2 diabetes - Impact of tirzepatide on FIB-4 in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058784

Enrollment

Registered

2025-08-15

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabete

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were administered tirzepatide

Exclusion criteria

Exclusion criteria: Patients with an observation period of less than 6 months

Design outcomes

Primary

Measure	Time frame
Changes in FIB-4 over 6 months after starting tirzepatide administration	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results